TY - JOUR
T1 - Promoter methylation of MCAM, ERa and ERβ in serum of early stage prostate cancer patients
AU - Brait, Mariana
AU - Banerjee, Mithu
AU - Maldonado, Leonel
AU - Ooki, Akira
AU - Loyo, Myriam
AU - Guida, Elisa
AU - Izumchenko, Evgeny
AU - Mangold, Leslie
AU - Humphreys, Elizabeth
AU - Rosenbaum, Eli
AU - Partin, Alan
AU - Sidransky, David
AU - Hoque, Mohammad Obaidul
PY - 2017
Y1 - 2017
N2 - Background: Prostate cancer (PC) is the second most common cancer among men worldwide. Currently, the most common non-invasive approach for screening and risk assessment of PC is measuring the level of serum prostate-specific antigen (PSA). However, the sensitivity of PSA is 42.8 % and specificity is 41.1%. As a result, the serum PSA test leads to numerous unneeded biopsies. Therefore, a rigorous search for biomarkers for early detection of PC is ongoing. In this study, we aim to assess a panel of epigenetic markers in an intend to develop an early detection test for PC. Results: The sensitivity and specificity of hypermethylation of MCAM was 66% and 73% respectively which is an improvement from the sensitivity and specificity of PSA. Considering a combination marker panel of MCAM, ERa and ERβ increased the sensitivity to 75% and the specificity became 70% for the minimally invasive early detection test of PC. Materials and Methods: Sixteen primary matched tumor and serum were analyzed by quantitative methylation specific PCR (QMSP) to determine analytical and clinical sensitivity of the genes tested (SSBP2, MCAM, ERa, ERβ, APC, CCND2, MGMT, GSTP1, p16 and RARβ2). Additionally, serum samples from eighty four cases of PC, thirty controls and seven cases diagnosed as high grade Prostatic Intraepithelial Neoplasia (HGPIN) were analyzed. Conclusions: Promoter methylation of MCAM, ERa and ERβ have a potential to be utilized as biomarker for the early detection of prostate PC as their sensitivity and specificity seem to be better than serum PSA in our cohort of samples. After robust validation in a larger prospective cohort, our findings may reduce the numbers of unwarranted prostate biopsies.
AB - Background: Prostate cancer (PC) is the second most common cancer among men worldwide. Currently, the most common non-invasive approach for screening and risk assessment of PC is measuring the level of serum prostate-specific antigen (PSA). However, the sensitivity of PSA is 42.8 % and specificity is 41.1%. As a result, the serum PSA test leads to numerous unneeded biopsies. Therefore, a rigorous search for biomarkers for early detection of PC is ongoing. In this study, we aim to assess a panel of epigenetic markers in an intend to develop an early detection test for PC. Results: The sensitivity and specificity of hypermethylation of MCAM was 66% and 73% respectively which is an improvement from the sensitivity and specificity of PSA. Considering a combination marker panel of MCAM, ERa and ERβ increased the sensitivity to 75% and the specificity became 70% for the minimally invasive early detection test of PC. Materials and Methods: Sixteen primary matched tumor and serum were analyzed by quantitative methylation specific PCR (QMSP) to determine analytical and clinical sensitivity of the genes tested (SSBP2, MCAM, ERa, ERβ, APC, CCND2, MGMT, GSTP1, p16 and RARβ2). Additionally, serum samples from eighty four cases of PC, thirty controls and seven cases diagnosed as high grade Prostatic Intraepithelial Neoplasia (HGPIN) were analyzed. Conclusions: Promoter methylation of MCAM, ERa and ERβ have a potential to be utilized as biomarker for the early detection of prostate PC as their sensitivity and specificity seem to be better than serum PSA in our cohort of samples. After robust validation in a larger prospective cohort, our findings may reduce the numbers of unwarranted prostate biopsies.
KW - Early detection
KW - Methylation
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85014074302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014074302&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.14873
DO - 10.18632/oncotarget.14873
M3 - Article
C2 - 28147335
AN - SCOPUS:85014074302
SN - 1949-2553
VL - 8
SP - 15431
EP - 15440
JO - Oncotarget
JF - Oncotarget
IS - 9
ER -